Results 21 to 30 of about 48,812 (228)

The price of tumor control [PDF]

, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Berking, Carola, Bockmeyer, Clemens L., Voskens, Caroline J., Fluck, Michael, Heinzerling, Lucie M., Schuler, Gerold, Vaubel, Julia, Keller, Ullrich, Goldinger, Simone M., Wilhelm, Tabea, Moos, Roger von, Mohr, Peter, Eigentler, Thomas, Paetzold, Sylvie, Justich, Armin, Hundorfean, Gheorghe, Hauschild, Axel, Mateus, Christine, Klein, Christina, Loquai, Carmen, Schadendorf, Dirk, Göppner, Daniela, Robert, Caroline, Bergmann, Tanja, Gutzmer, Ralf, Hein, Rüdiger, Grabbe, Stephan, Dummer, Reinhard, Kaehler, Katharina C., Trefzer, Uwe, Ulrich, Jens, Weder, Patrik, Schuler-Thurner, Beatrice, Garbe, Claus, Satzger, Imke, Schlaeppi, Marc   +35 more
core   +1 more source

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

, 2023
lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IVmelanoma,with benefit sustained at 4 years.
Gogas, Helen, Arance Fernandez, Ana M., Del Vecchio, Michele, Weber, Jeffrey, Larkin, James, Mandalá, Mario, Dalle, Stéphane, Cruz Merino, Luis de la   +7 more
core   +1 more source

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

BMC Cancer, 2020
Background For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment’s real-world effectiveness.
Wei Fang Dai, Jaclyn M. Beca, Ruth Croxford, Wanrudee Isaranawatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Timothy P. Hanna, Kelvin K.W. Chan   +10 more
doaj   +1 more source

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Journal for ImmunoTherapy of Cancer, 2022
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1 ...
Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, Andrew M Haydon   +46 more
doaj   +1 more source

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Health and Quality of Life Outcomes, 2012
Background In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients.
Revicki Dennis A, van den Eertwegh Alfons JM, Lorigan Paul, Lebbe Celeste, Linette Gerald, Ottensmeier Christian H, Safikhani Shima, Messina Marianne, Hoos Axel, Wagner Samuel, Kotapati Srividya   +10 more
doaj   +1 more source

Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma

Case Reports in Endocrinology, 2016
Objective. Thyroid disease has been reported among the endocrinopathies that can occur after treatment with ipilimumab. Graves’ disease, however, has been rarely reported with this medication.
Umal Azmat, David Liebner, Amy Joehlin-Price, Amit Agrawal, Fadi Nabhan   +4 more
doaj   +1 more source

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer

Frontiers in Pharmacology, 2021
Purpose: The effectiveness of nivolumab plus ipilimumab for advanced non-small cell lung cancer (NSCLC) has been demonstrated. Decisions have to be made about allocating healthcare resources.
Xuezhi Hao, Aizong Shen, Bin Wu
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Acute visual loss after ipilimumab treatment for metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).Case ...
Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher   +8 more
doaj   +1 more source

Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

PLoS ONE, 2023
ObjectivesThe treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.Materials and methodsWe
Gu-Shun Lai, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang   +8 more
doaj   +1 more source